We pioneered research establishing stress granules (SGs) as critical survival organelles in KRAS-driven cancers. We first discovered that oncogenic KRAS upregulates SG formation via MAPK-driven prostaglandin pathways (15-d-PGJ2) to enhance cellular fitness, suppress apoptosis, and confer resistance to stress and chemotherapy (Grabocka & Bar-Sagi, Cell, 2016).